daunorubicin has been researched along with Vitreoretinopathy, Proliferative in 16 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (56.25) | 18.2507 |
| 2000's | 4 (25.00) | 29.6817 |
| 2010's | 3 (18.75) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chiquet, C; Rouberol, F | 1 |
| Cheng, L; Freeman, WR; Hou, H; Huffman, K; Rios, S; Sailor, MJ | 1 |
| Moysidis, SN; Thanos, A; Vavvas, DG | 1 |
| Choudhary, I; Kumar, A; Nainiwal, S; Tewari, HK; Verma, LK | 1 |
| Laroche, L; Morel, C; Sahel, JA; Scheer, S; Touzeau, O | 1 |
| Ciechanowski, C; Gebka, A; Iwaszkiewicz-Bilikiewicz, B; Raczyńska, K | 1 |
| Chen, YH; Hu, DN; Kuo, HK; Wu, PC; Wu, YC; Yang, PM | 1 |
| Borhani, H; el-Sayed, SH; Fernandes, ML; Luo, Q; Peyman, GA; Rahimy, MH | 1 |
| Green, WR; Heimann, K; Mietz, H; Walshe, R; Wiedemann, P | 1 |
| Bathwal, DP; Khosla, PK; Kumar, A; Tewari, HK | 1 |
| Bartz-Schmidt, KU; Esser, P; Heimann, K; Kaszli, F; Walter, P; Weller, M | 1 |
| Hida, T; Hirakata, A; Horie, E; Inoue, M; Miki, D; Yata, K | 1 |
| Bartz-Schmidt, KU; Esser, P; Heimann, K; Kociok, N; Tervooren, D; Walter, P; Weller, M | 1 |
| Bauer, P; Heimann, K; Hilgers, RD; Wiedemann, P | 1 |
| Wiedemann, P | 1 |
| Hu, D; Hui, YN | 1 |
3 review(s) available for daunorubicin and Vitreoretinopathy, Proliferative
| Article | Year |
|---|---|
[Proliferative vitreoretinopathy: prophylactic treatment].
Topics: Antibiotics, Antineoplastic; Colchicine; Daunorubicin; Fibrinolytic Agents; Fluorouracil; Glucocorticoids; Heparin; Humans; Immunosuppressive Agents; Intravitreal Injections; Keratolytic Agents; Retinal Detachment; Tretinoin; Tubulin Modulators; Vitreoretinopathy, Proliferative | 2014 |
Mechanisms of inflammation in proliferative vitreoretinopathy: from bench to bedside.
Topics: Animals; Clinical Trials as Topic; Daunorubicin; Fluorouracil; Heparin, Low-Molecular-Weight; Humans; Inflammation; Isotretinoin; Receptor, Platelet-Derived Growth Factor alpha; Vitreoretinopathy, Proliferative | 2012 |
[Pharmacological adjuvants for surgical treatment of proliferative vitreoretinopathy].
Topics: Chemotherapy, Adjuvant; Clinical Trials as Topic; Daunorubicin; Glucocorticoids; Heparin; Humans; Vitreoretinopathy, Proliferative | 2004 |
3 trial(s) available for daunorubicin and Vitreoretinopathy, Proliferative
| Article | Year |
|---|---|
Role of daunorubicin in inhibiting proliferative vitreoretinopathy after retinal detachment surgery.
Topics: Antibiotics, Antineoplastic; Daunorubicin; Female; Humans; Injections; Male; Middle Aged; Retinal Detachment; Scleral Buckling; Visual Acuity; Vitrectomy; Vitreoretinopathy, Proliferative; Vitreous Body | 2002 |
[Vitrectomy with daunorubicin].
Topics: Adult; Daunorubicin; Female; Follow-Up Studies; Gentamicins; Humans; Male; Middle Aged; Retinal Detachment; Retinal Perforations; Secondary Prevention; Treatment Outcome; Vitrectomy; Vitreoretinopathy, Proliferative | 2004 |
Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Chemotherapy, Adjuvant; Daunorubicin; Female; Follow-Up Studies; Humans; Male; Middle Aged; Prospective Studies; Safety; Scleral Buckling; Treatment Outcome; Visual Acuity; Vitrectomy; Vitreoretinopathy, Proliferative | 1998 |
10 other study(ies) available for daunorubicin and Vitreoretinopathy, Proliferative
| Article | Year |
|---|---|
A Novel Approach of Daunorubicin Application on Formation of Proliferative Retinopathy Using a Porous Silicon Controlled Delivery System: Pharmacodynamics.
Topics: Animals; Daunorubicin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Delivery Systems; Porosity; Rabbits; Silicon; Topoisomerase II Inhibitors; Vitreoretinopathy, Proliferative; Vitreous Body | 2015 |
Effects of topoisomerase II inhibitors on retinal pigment epithelium and experimental proliferative vitreoretinopathy.
Topics: Animals; Cell Survival; Cells, Cultured; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug-Related Side Effects and Adverse Reactions; Enzyme Inhibitors; Etoposide; In Vitro Techniques; Injections; Male; Maximum Tolerated Dose; Pigment Epithelium of Eye; Rabbits; Topoisomerase II Inhibitors; Vitreoretinopathy, Proliferative; Vitreous Body | 2007 |
Effects of an intravitreal daunomycin implant on experimental proliferative vitreoretinopathy: simultaneous pharmacokinetic and pharmacodynamic evaluations.
Topics: Animals; Biological Availability; Cell Division; Cells, Cultured; Daunorubicin; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Carriers; Drug Implants; Fluorophotometry; Pigment Epithelium of Eye; Rabbits; Random Allocation; Retinal Detachment; Time Factors; Vitreoretinopathy, Proliferative; Vitreous Body | 1994 |
Histopathologic study of epiretinal proliferations after vitrectomy with daunomycin and silicone oil.
Topics: Adult; Astrocytes; Cell Membrane; Collagen; Cryosurgery; Daunorubicin; Female; Fibroblasts; Humans; Macrophages; Male; Middle Aged; Pigment Epithelium of Eye; Recurrence; Reoperation; Scleral Buckling; Silicone Oils; Vitrectomy; Vitreoretinopathy, Proliferative | 1994 |
Experimental inhibition of proliferative vitreoretinopathy in retinal detachment using daunorubicin.
Topics: Animals; Cell Division; Daunorubicin; Electroretinography; Fibroblasts; Fundus Oculi; Half-Life; Rabbits; Retina; Retinal Detachment; Vitreoretinopathy, Proliferative | 1994 |
Apoptotic cell death in proliferative vitreoretinopathy.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Apoptosis; Cell Division; Cells, Cultured; Child, Preschool; Daunorubicin; Enzyme-Linked Immunosorbent Assay; Humans; Middle Aged; Retina; Vitreoretinopathy, Proliferative | 1996 |
[Proliferative vitreoretinopathy treated with daunorubicin].
Topics: Adolescent; Adult; Antibiotics, Antineoplastic; Daunorubicin; Female; Humans; Male; Middle Aged; Prognosis; Reoperation; Vitrectomy; Vitreoretinopathy, Proliferative | 1997 |
Intravitreal daunomycin induces multidrug resistance in proliferative vitreoretinopathy.
Topics: Adolescent; Adult; Aged; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Culture Techniques; Chemotherapy, Adjuvant; Child, Preschool; Daunorubicin; Drug Resistance, Multiple; Female; Glial Fibrillary Acidic Protein; Humans; Immunoenzyme Techniques; Keratins; Male; Middle Aged; Pigment Epithelium of Eye; Polymerase Chain Reaction; RNA, Messenger; Transcription Factors; Vitreoretinopathy, Proliferative; Vitreous Body | 1998 |
1998 Jules Gonin lecture of the Retina Research Foundation. Drug treatment of ocular neovascularization and proliferation.
Topics: Calcium Channel Blockers; Cell Adhesion; Cell Movement; Cell Survival; Daunorubicin; Humans; Immunotoxins; Integrins; Multicenter Studies as Topic; Peptides, Cyclic; Pigment Epithelium of Eye; Retinal Neovascularization; Triazoles; Vitreoretinopathy, Proliferative | 1999 |
Prevention of experimental proliferative vitreoretinopathy with daunomycin and triamcinolone based on the time course of the disease.
Topics: Animals; Autoradiography; Cell Division; Daunorubicin; Disease Models, Animal; Drug Administration Schedule; Drug Therapy, Combination; Female; Inflammation; Macrophages; Male; Rabbits; Retinal Detachment; Triamcinolone; Vitreoretinopathy, Proliferative | 1999 |